Exhibit 99.1



                       CDEX PROJECTS RECORD PLACEMENTS OF
                          VALIMED(TM) MVS UNITS IN 2010

Tucson, Arizona - December 2, 2009 - CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com)
CEO and Chairman, Malcolm Philips, reviews CDEX's performance through 2009 and
sets the stage for 2010 in the "CEO Corner" of the CDEX Web Site. Mr. Philips
reflected upon CDEX's progress through the global economic downturn of 2009,
concluding that based on recent sales activity 2010 will be a year of record
placements of ValiMed(TM) MVS units, driven by improving economic conditions and
the recent introduction of the "Pay Per Use" pricing plan for hospitals. The
list of world class hospitals that have made ValiMed MVS a part of their
Medication Safety and Narcotic Return Validation Programs continues to grow and
lives are being saved. In addition, Tim Shriver, CDEX COO, provides a management
briefing update on technological advancements in the CDEX product lines. For a
complete review of the briefings, please go to the "CEO Corner" of the
Management Briefing section of the CDEX Web Site (www.cdexinc.com).

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare
and security markets. The ValiMed product line provides life-saving validation
of high-risk medications and returned narcotics. The ID2(TM) product line
detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to
advance its patented technologies to serve additional markets. To meet its
plans, CDEX must strengthen its financial position as stated periodically in its
SEC filings. For more information, contact Malcolm Philips at
mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities
laws, and generally can be identified by words such as "expects," "plans,"
"may," "believes," "should," "intends," and similar words. These statements pose
risks that cannot be accurately predicted. Consequently, results may differ
materially from those expressed or implied. Such risks and uncertainties
include, without limitation, the effectiveness, profitability and marketability
of products, the protection of intellectual property and proprietary
information, and other risks detailed periodically in filings with the SEC.
There is no obligation to update any forward-looking statements.



4555 S. Palo Verde Rd. Suite 123 Tucson, AZ 85714 (520) 745-5172 www.cdexinc.com